FDA Approves RSV Monoclonal Antibody for Infants and Young Children
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION(2023)
Abstract
Nirsevimab-alip, marketed as Beyfortus by AstraZeneca, has received US Food and Drug Administration authorization for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children up to 2 years old.
MoreTranslated text
Key words
rsv monoclonal antibody,monoclonal antibody,infants,young children
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined